Omeros Gets FDA Approval of Yartemlea

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
MedPage Today on MSN

First Drug for Deadly Transplant Complication Gets FDA's Blessing

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
Hoodline

Gov. Newsom Declares State of Emergency in Multiple California Counties Amid Severe Storms

Gov. Newsom declared a state of emergency in several Californian counties due to severe weather risks, such as flooding and ...

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Nature

Complement evasion by human pathogens

The human complement system has a pivotal role in the recognition, opsonization and elimination of microbial intruders. This functionality is maintained by a well-balanced interaction network of serum ...
The Caledonian-Record

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
The Punch

Borno bomb blast sparks heightened security nationwide

A deadly Borno bomb blast at a Maiduguri mosque prompts a nationwide security scale-up, with thousands of operatives deployed ...
Medical Dialogues

FDA Approves First Treatment for HSCT-Associated Thrombotic Microangiopathy

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...
The Punch on MSN

Fire, loss, uncertainty: Inside Gombe’s Kasuwar Katako Timber Market tragedy

A devastating fire at Gombe's Kasuwar Katako Timber Market destroyed goods worth N600m, leaving over 60 traders facing ...
Yardbarker on MSN

Browns will not activate Deshaun Watson from PUP list

Rather than moving the high-priced quarterback to the active roster and allowing more practice work, the Browns are shutting ...
MedPage Today on MSN

FcRn Blockers Vie to Become First Approved Drug for Sjogren's Disease

FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...